In search of red blood cells for alloimmunized patients with sickle cell disease by Flickinger, Cynthia
Patients with sickle cell disease (SCD) typically require transfusions
with RBC components, which exposes them to numerous, possibly
foreign antigens and potentially causes them to produce an
antibody or antibodies to the antigens they lack. As transfusion of
these patients increases, the likelihood that they will produce an
initial antibody or additional antibodies increases. Once a clinically
significant antibody is produced, units of RBCs that lack the
associated antigen should be transfused. Often patients with SCD
present to the transfusion service with numerous antibodies in
their serum, making the search for compatible RBCs a challenge.
The American Rare Donor Program (ARDP) has been used to search
for RBCs to meet the transfusion needs of this patient population.
Between January 2005 and June 2006, approximately 33 percent of
the requests to the ARDP for RBC components were for
alloimmunized patients with SCD. Of these requests, 94.9 percent
were completely or partially filled; requests for r"r", Hy–, and E–,
hrS– units of RBCs were among the most difficult to fill. This article
will discuss the use and effectiveness of the ARDP and testing
laboratories associated with the National Reference Laboratory for
Blood Group Serology at the American Red Cross in obtaining
compatible RBCs for alloimmunized patients with SCD.
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Patients with sickle cell disease (SCD) typically
require RBC transfusions for treatment of the severe
anemia indicative of the disorder and to alleviate the
clinical symptoms or prevent the complications of the
disease.1–7 Patients with SCD who require chronic
transfusion support have increased exposure to foreign
RBC antigens; this exposure increases not only the
likelihood that antibodies will be produced, but also
the number of specificities.8,9 The incidence of
alloimmunization to RBC antigens within this
population has been reported as 5 to 40 percent.8,10–12
Alloimmunization can be reduced by transfusing
phenotypically matched RBCs.13–15 Such units may be
found in ethnically matched donors, from directed
donors, or by phenotyping donor RBC compo-
nents.8,13,14-17 Although there is a 93 percent probability
that RBCs of the E–, C–, Fy(a–), K–, Jk(b–) phenotype
would be from an African American donor, only about
10 percent of African Americans in an urban
population donate, making it difficult to support the
transfusion needs of patients with SCD with these
RBCs alone.16 On the other hand, although about 90
percent of Caucasian donors in this same setting
donate, there is only a 7 percent probability that their
RBCs would be of this phenotype. This disparity in
phenotype increases the time and testing resources
needed to obtain phenotype-matched RBCs which may
not be cost-effective.9,14,17
Many transfusion services have defined protocols
by which they attempt to reduce the alloimmunization
of this patient population, while minimizing testing
time and resources. These protocols range from
providing limited phenotype-matched RBCs for only C,
c, E, and e to providing extended phenotype-matched
RBCs for C, c, E, e, K, S, Fya, and Jkb. Castro et al.
concluded that limited phenotype matching for C, c, E,
e, and K would have prevented alloimmunization in
53.3 percent of the patients in their study and
extended phenotype matching would have prevented
70.8 percent.15 While it would be beneficial to always
provide extended phenotype-matched RBCs, these
phenotypes are 22.7 times less prevalent among
random blood donors, making the testing costly and
labor intensive.15,17 In addition, considering the
emergent nature of sickle cell crisis15 and the transient
nature of patients with SCD who may be treated at
various facilities with differing transfusion protocols, it
may not be practical to think that all patients with SCD
could receive extended phenotype-matched RBCs.
Transfusing such patients with nonphenotype-matched
RBCs may become necessary, negating the positive
effects of previous adherence to a phenotype-matched
transfusion protocol.17
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Although transfusion services may establish
protocols to reduce alloimmunization, patients with
SCD who receive RBC transfusions often do produce
antibodies.1,8,12 Specificities of the antibodies produced
may be as few as one or as many as more than ten and
may include an antibody to a high-incidence antigen.8
Finding compatible RBCs is often a challenge for the
routine transfusion service.
Use of the American Rare Donor Program
Overview and rare donor criteria
The American Rare Donor Program (ARDP), formed
in 1998 as a merger of the donor databases of the AABB
and the American Red Cross (ARC), is a source for
obtaining units of rare RBCs. Currently, the ARDP data-
base has phenotype information on more than 35,000
active rare donors in the United States,Puerto Rico,and
Milan, Italy. RBCs collected from these rare donors are
available to the 81 ARDP member facilities upon
request. In addition, nonmember facilities with a
transfusion request for rare RBCs may access the ARDP
by contacting a member facility, making the services of
the ARDP available to all transfusion services and to all
patients, both nationally and internationally.
The ARDP is governed by a standard operating
procedure (SOP) approved by members of the ARDP
advisory committee. This SOP provides guidelines for
membership and procedural steps for accessing the
ARDP for donor submissions and patient requests.
Demographic and rare phenotype information on
donors is submitted by ARDP members, reviewed for
appropriateness and completeness, and entered into
the database. According to the current ARDP SOP, a
donor RBC phenotype is considered rare if it meets one
of the following criteria:
1. Group O and group A; R1R1, R2R2, R0R0, or rr; and
K:–1; and Fy(a–) or Fy(b–); and Jk(a–) or Jk(b–);
and S– or s–
2. Group O and group A;R1R1,R2R2,or rr;and K:–1;
and Fy(a–b–)
3. All ABO groups; negative for a high-incidence
antigen (1/10,000), such as U, Jsb, Kpb, Yta, or
Ge:-2
Searching for rare units of RBCs
Patient phenotype requests are entered into the ARDP
database and matched with member facilities having
registered donors. These facilities are then contacted
to determine RBC component availability. If compo-
nents are not available, the ARDP system manager will
expand the search to include recruiting donors,
collecting autologous units, testing family members or,
if both RBC components and donors are not available
in the United States, initiating an international search.
In addition, if an antibody to a high-incidence
antigen is demonstrable in the patient’s serum and
antigen-negative RBCs are not available, the transfusion
service may be advised to send the patient’s blood
sample to the National Reference Laboratory for Blood
Group Serology at the ARC for a monocyte monolayer
assay (MMA). MMA results can determine the probable
clinical significance of that antibody and may allow the
transfusion of RBCs that are antigen-positive, if
transfusion is imminent.18
Although somewhat effective at procuring rare
RBCs or easing phenotype requirements, these
additional search efforts are no substitute for having
rare RBCs available in inventory when needed.
Recruitment efforts are never a guarantee that a
transfusable unit will be obtained. The recruiters may
be unable to contact the donor, the donor may be
temporarily deferred, unwilling, or unable to donate, or
the frequency of the transfusion requests may infringe
on the 56-day wait requirement between donations.
Autologous donations depend on the clinical condition
of the patient and family member testing relies on the
availability and willingness of family members to be
tested as well as the likelihood that their RBC
phenotype will be a match.
Importing rare RBCs through an international
search is regulated by the FDA with strict guidelines
requiring that the physician and patient acknowledge
the unlicensed nature of all imported units of RBCs. In
addition, imported RBCs cannot be transfused to any
other patient, leaving them to be discarded if not
transfused to the designated patient.
Effectiveness of the ARDP
Although the database currently stores information
on more than 35,000 active rare donors, RBCs are not
always available at the member facilities when needed
to fill a transfusion request. Table 1 shows the
effectiveness of the ARDP in filling all patient requests
and in filling requests for patients with SCD from
January 1, 2005 through June 30, 2006. Approximately
33 percent (351/1070) of the total requests were for
patients with SCD; of these, 94.9 percent were
completely or partially filled compared with an overall
ARDP fill rate of 93.6 percent. On the basis of the rare
donor criteria defined in the ARDP SOP, 210 (59.8%) 
of the 351 requests were for multiple common antigen-
negative RBCs and 141 (40.2%) were for high-
incidence antigen-negative RBCs.
Of the 210 requests for multiple common antigen-
negative RBCs, 209 (99.5%) were filled (Table 2). The
one unfilled request (0.5%) was for rr RBCs, an
expected statistic considering that only 6.8 percent of
the RBCs within the African American population are
of the rr phenotype and only 8.0 percent of the RBCs
within the Caucasian population
are of the K–, Fy(a–), Jk(b–)
phenotype.19
Of the 141 requests for high-
incidence antigen negative RBCs,
124 (87.9%) were filled (Table 3).
The most difficult RBCs to find for
this patient population included
the phenotypes Jo(a–), Hy–, and
r"r" (The request for r"r" also
required the RBCs to be Jk[b–]).
In addition, requests for Ge:–2,
and for E–, hrS– RBCs were
completely unfilled. (The RBCs
for the Ge:–2 request had to be
C–, E–, K–, Fy(a–), and S– and
those for the E–, hrS– request had
to be C-; there were no registered
phenotype-matched donors in the
database for either of these
requests.)  It is interesting to note
that the four requests for E–, hrB–
RBCs were completely or partially
filled. This will be discussed in a
later section.
Impact of antibodies to high-
and low-incidence antigens on
the fill rate
Although not typically consid-
ered clinically significant and the
associated antigens are not
included in the rare phenotype
criteria defined in the ARDP SOP,
antibodies against M, N, P1, Lea, or
Leb antigens may be clinically
significant. If determined as such
by the ARDP member facility,
these antigens would be added to
the RBC search. In addition,
requests for RBCs negative for low-incidence antigens
would add an extra challenge to the component
search;antisera resources are limited and most facilities
do not routinely type donor RBCs for these antigens
before submitting them to the ARDP. Segments from
liquid RBCs or deglycerolized RBC segments would
need to be tested. If frozen segments are not available,
the requesting facility may need to determine if the risk
of waiting for another component of the needed
phenotype is worth that of receiving the frozen RBC
unit and typing it after it is deglycerolized. This
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Table 1. ARDP requests for rare RBCs (January 1, 2005 to June 30, 2006)
Total
number
of requests Number % Number % Number %
All patients 1070 912 85.2 90 8.4 68 6.4




partially filled Requests unfilled
Table 2. ARDP requests for common multiple antigen–negative RBCs for patients with SCD 
(January 1, 2005 to June 1, 2006)
Total number
Requested of requests
phenotype (n = 210) Number % Number % Number %
R0* 101 101 100 0 – 0 –
rr† 53 45 84.9 7 13.2 1 1.9
R1
† 41 39 95.1 2 4.9 0 –
R2
† 15 15 100 0 – 0 –
Total 210 200 95.2 9 4.3 1 0.5
*K:–1; and Fy(a–) or Fy(b–); and Jk(a–) or Jk(b–); and S– or s– 




partially filled Requests unfilled
Table 3. ARDP requests for high-incidence–negative RBCs for patients with SCD 
(January 1, 2005 to June 1, 2006)
Total number
Requested of requests
phenotype (n = 141) Number % Number % Number %
U–,D+ 62 47 75.8 8 12.9 7 11.3
Js(b–) 42 40 95.2 1 2.4 1 2.4
U–,D– 8 5 62.5 2 25.0 1 12.5
r”r” 7 1 14.3 4 57.1 2 28.6
Hy– 6 1 16.7 3 50.0 2 33.3
Jo(a–) 5 2 40.0 1 20.0 2 40.0
E–,hrB– 4 3 75.0 1 25.0 0 –
Lu(b–) 2 2 100 0 – 0 –
k– 2 2 100 0 – 0 –
I– 1 0 – 1 100 0 –
Ge:–2 1 0 – 0 – 1 100
E–,hrS– 1 0 – 0 – 1 100




partially filled Requests unfilled
presents a challenge to the
transfusion service and to the
medical staff caring for the
patient.
Table 4 shows the fill rates for
requests for rare RBCs required to
be negative for multiple common
antigens as well as for additional
antigens within the M, N, P1, Lea,
or Leb group, for one or more low-
incidence antigens, or for both.
Of the 210 requests, 108 (51.4%)
required that the RBCs be
negative for additional antigens
such as M,N,P1,Lea,or Leb,or low-
incidence antigens,such as Cw, Jsa,
Kpa,V, or VS or both; only 1 of the
210 (0.5%) requests was unfilled.
The fill rates for the requests
for high-incidence antigen-
negative RBCs shifted toward an
increase in the need for additional
antigens to be negative as well as
an increase in unfilled requests
(Table 5). Of the 141 requests,
130 (92.1%) also required that the
RBCs be negative for some or all
of the common multiple antigens
as defined in the ARDP SOP 
(86 requests) or that additional
antigens be negative (44
requests). Of the 141 requests, 18
(12.8%) were unfilled.
The ARDP was able to provide
RBCs for 99.5 percent of the
requests for patients with SCD
needing multiple common
antigen-negative RBCs, reflecting
the fact that these phenotypes are
indicative of the rare criteria
defined in the ARDP SOP, are
common among the African
American donor population, and
although not prevalent, are found
in the predominantly Caucasian
donor population. Obtaining
RBCs became more difficult when
the requests switched to high-
incidence antigen-negative RBCs
more characteristic of the African
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Table 4. ARDP requests for multiple common antigen–negative RBCs, with and without additional
antigen needs (January 1, 2005 to June 30, 2006)
Total number
Requested of requests
phenotype (n = 210) Number % Number % Number %
Multiple common 92 87 94.6 5 5.4 0 –
antigens*
Multiple common 44 43 97.7 1 2.3 0 –
antigens* and M– or N– 
or Le(a–) or Le(b–) and 
low-incidence antigen
Multiple common 43 42 97.7 1 2.3 0 –
antigens* and 
low-incidence antigen
Multiple common 31 28 90.3 2 6.5 1 3.2
antigens* and M– or N– 
or Le(a–) or Le(b–)
Total 210 200 95.2 9 4.3 1 0.5





partially filled Requests unfilled
Table 5. ARDP requests for high-incidence antigen–negative RBCs, with and without additional antigen
needs (January 1, 2005 to June 30, 2006)
Total number
Requested of requests
phenotype (n = 141) Number % Number % Number %
High-incidence 86 67 77.9 12 14.0 7 8.1
antigen and multiple 
common antigens*
High-incidence 16 15 93.8 1 6.2 0 –
antigen and multiple 
common antigens* 
and M– or N– or 
Le(a–) or Le(b–)
High-incidence 14 7 50 2 14.3 5 35.7
antigen and multiple 
common antigens* 
and M– or N– or 
Le(a–) or Le(b–) and 
low incidence antigen
High-incidence 12 7 58.3 2 16.7 3 25.0
antigen and multiple 
common antigens* and 
low incidence antigen
High-incidence 11 5 45.4 3 27.2 3 27.2
antigen
High-incidence 1 1 100 0 – 0 –
antigen, M– or N– 
or Le(a–) or Le(b–)
High-incidence 1 1 100 0 – 0 –
antigen and M– or 
N– or Le(a–) or Le(b–) 
and low incidence
Total 141 103 73.0 20 14.2 18 12.8
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American population, for example, U– or Js(b–)
(87.2%). For these requests, it may have been useful to
perform additional testing, such as the MMA, or to
initiate an international search for the desired RBCs.
Expanded search efforts
As presented earlier,94.9 percent of the transfusion
requests for patients with SCD were filled. This fill rate
was achieved, in part, by the ARDP system manager’s
expanded search efforts. Generally, such efforts to
obtain RBCs for these patients are limited. These
patients are not candidates for autologous transfusion;
the genetic abnormality of their RBCs creates the
clinical symptoms and transfusion needs characteristic
of the disease. MMA testing may not be useful in
assessing the clinical significance of an antibody to a
high-incidence antigen; the typical antibodies
produced by these patients are historically known to
be clinically significant, such as anti-U, -Jsb, and -Kpb.
Family member testing may not be effective; family
members may have HbS trait or SCD and would not be
suitable donors. Donor recruitment and international
searches may be the main mechanisms for procuring
RBCs for this patient population.
In addition, the variant nature of the genotypes
within the Rh blood group system does not always
ensure that antigen-negative RBCs will be serologically
compatible. In particular, e variants, hrB– and hrS–,
common in individuals of African descent, are
notorious for this disparity and have created additional
challenges for the ARDP to provide RBCs for patients
with SCD and to safeguard against the unnecessary
shipment of rare components. To help reduce the risk
to rare components, ARDP works with the molecular
testing laboratory at the Penn-Jersey Region of the ARC
in Philadelphia to provide RH molecular character-
ization of patient and potential donor samples to
determine compatibility. Donor testing is especially
beneficial for creating a database of molecularly
characterized units that can then be genotypically
matched to future patients’ needs, ensuring compat-
ibility and reducing the alloimmunization of these
patients.
Challenging phenotypes
Since April of 2000,29 requests for rare RBCs of the
phenotype group O, r"r", K:-1, Jk(b–) have been
submitted to the ARDP. Only 12 donors with this
phenotype are in the ARDP database, 3 of whom are
more than 75 years old. With only nine potential
donors, it was often unlikely that components of this
phenotype were available when needed and
recruitment efforts were typically undertaken. As
stated previously, recruitment efforts are never a
guarantee that a transfusable unit will be obtained.
Interestingly, RBCs of this phenotype were obtained 
for 24 of the 29 requests, attributing much to the 
ARDP, its members, and its donors.
Another difficult phenotype request to fill was that
for group O, R2R2, U– RBCs. Since October 2002, 11
requests have been submitted to the ARDP for this
phenotype. Only 7 donors with this RBC phenotype
were in the database and again, RBCs were not
available and recruitment efforts were undertaken.
However, in this case, only 4 of the requests resulted in
units of RBCs; recruitment efforts were not as effective.
Although not made as often as those for RBCs
negative for multiple common antigens, requests for e
variant RBCs, such as hrB– or hrS–, do occur (Table 2).
These requests present additional challenges to the
ARDP because of the low number of donors with these
phenotypes and of the diversity of the variants. Even if
antigen-negative RBCs are located, they may be
incompatible with the serum of the patient. In
addition, the patient may have other antibodies,
narrowing the search for and the availability of
compatible RBCs. Requests for RBCs began in March
1996 for the following phenotype: group O, R0, K:–1,
Fy(a–b–), S–, and hrB–. Although there were no
registered donors in the database, antigen-negative
RBCs were located in the United States and were
transfused. Additional requests in April 1996 and July
1996 also resulted in compatible RBCs within the
United States. Requests for rare RBCs of this
phenotype were not submitted to the ARDP again until
July 2002, at which time RBCs were not located in the
United States nor were components located for the
same request in December 2003. In July 2005, the
requesting facility requested that an international
search be initiated. Contact with the South African
National Blood Service in South Africa procured two
units in July 2005 and again in March 2006.
In April 2005, the ARDP received a request for RBCs
of the phenotype group O, R1R1, Jk(b–), and hr
B–. Five
donors with RBCs of that phenotype were in the ARDP
database; all were contacted. One donor no longer
donated because of age, but the other four donors
responded to the recruitment effort. One donor was
deferred; the other three donated at various ARDP
member facilities across the United States. Samples from
C. FLICKINGER
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each of the donors and from the patient were sent to the
molecular testing lab at the American Red Cross in
Philadelphia for genotyping. Once the donors with the
best genotype match were determined, their liquid units
of RBCs were shipped to the transfusing site.
Summary
Patients with SCD present challenges to transfusion
services because of the numerous antibody specific-
ities they may produce, the numerous times that they
may be transfused, the disparity between the RBC
phenotype of the African American patient population
and that of the predominantly Caucasian donor
population, and the variability within the genetic
makeup of their RBC antigens. Some transfusion
services institute protocols for providing antigen-
negative RBCs for these patients to decrease
alloimmunization while others match only for ABO and
D. Donor populations, staffing,and testing resources all
influence the transfusion protocols chosen by these
services. Regardless of the selected protocol, the ARDP
serves as a critical source for rare RBCs needed for
patients with SCD.
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